Article Dans Une Revue Kidney International Reports Année : 2020

A Randomized Prospective Study Comparing Anti–T-Lymphocyte Igs to Basiliximab in Highly Sensitized Kidney Transplant Patients

Résumé

Background:Two prospective studies that were performed before the era of highly sensitive solid-phaseassays have shown a lower incidence of acute rejection in highly sensitized kidney-transplant patientsgiven polyclonal antibodies compared with those given anti-CD25 monoclonal antibodies.Methods:This prospective pilot randomized French multicenter study aimed to compare anti–T-lympho-cyte Ig (ATLG) (n¼32) and basiliximab (n¼27) in highly sensitized kidney-transplant patients withoutpreformed donor-specific antibodies (pDSAs) as assessed by a Luminex Single-Antigenflow bead assay.Only patients with a calculated panel reactive antibody$50%, with at least 1 antibody with a meanfluorescence intensity$5000 and without a historical pDSA and without a pDSA on the day of trans-plantation were included.Results:Treatment failure as defined by biopsy-proven acute rejection, patient lost to follow-up, graft loss,and death was observed in 18.8% (95% confidence interval [CI], 8.9%–37.1%) and 18.8% (95% CI, 8.9%–37.1%) in patients who received ATLG and 14.8% (95% CI, 5.8%–34.8%) and 28.2% (95% CI, 14.2%–51.2%) ofpatients who received basiliximab, respectively at 6 (P¼0.66) and 12 (P¼0.62) months post-transplantation.One T cell–mediated rejection was observed in ATLG-treated patients (3.1%). One antibody-mediatedrejection due to ade novodonor-specific antibody (DSA) occurred in basiliximab-treated patients (3.7%).Patient survival, graft survival, kidney parameters, and infection rate were similar in the 2 groups.Conclusion:This pilot study indicates that in highly sensitized kidney-transplant patients without pDSAs,both ATLG and basiliximab can be used efficiently and safely. However, because of the lack of power,these results should be interpreted with caution
Fichier principal
Vignette du fichier
KamarNassim_2020.pdf (1.24 Mo) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03163776 , version 1 (09-03-2021)

Identifiants

Citer

Nassim Kamar, Benoit Lepage, Lionel Couzi, Laetitia Albano, Antoine Dürrbach, et al.. A Randomized Prospective Study Comparing Anti–T-Lymphocyte Igs to Basiliximab in Highly Sensitized Kidney Transplant Patients. Kidney International Reports, 2020, 5 (8), pp.1207-1217. ⟨10.1016/j.ekir.2020.05.020⟩. ⟨hal-03163776⟩
67 Consultations
94 Téléchargements

Altmetric

Partager

More